Influence of Helicobacter pylori Infection on Gut and Tumor Microbiomes and Its Relationship with Immunotherapy Outcomes in Gastrointestinal Malignancies - Scorecard - MDSpire

Influence of Helicobacter pylori Infection on Gut and Tumor Microbiomes and Its Relationship with Immunotherapy Outcomes in Gastrointestinal Malignancies

  • By

  • Keren Jia

  • Yang Chen

  • Die Dai

  • Yi Xie

  • Haoxin Peng

  • Yanshuo Cao

  • Hua Zou

  • Chuangzhao Qiu

  • Yan Tan

  • Xiaotian Zhang

  • Zhihao Lu

  • Xiaochen Yin

  • Zhi Peng

  • Jian Li

  • Lin Shen

  • January 12, 2026

  • 0 min

Share

Clinical Scorecard: Influence of Helicobacter pylori Infection on Gut and Tumor Microbiomes and Its Relationship with Immunotherapy Outcomes in Gastrointestinal Malignancies

At a Glance

CategoryDetail
ConditionGastric Cancer (GC)
Key MechanismsH. pylori infection influences gut microbiome composition and may enhance immunotherapy efficacy.
Target PopulationPatients with gastrointestinal cancers, including GC, ESCC, and MSI-H colorectal cancer.
Care SettingOncology clinics providing immunotherapy treatments.

Key Highlights

  • H. pylori is a Group I carcinogen for gastric cancer.
  • H. pylori-positive patients show longer median immune-related progression-free survival (6.97 months vs. 5.03 months).
  • The gut microbiome may serve as an immunotherapy sensitizer.
  • Intratumoral microbiome is associated with prognosis and therapeutic response.
  • Rigorous inclusion and exclusion criteria were established for study participants.

Guideline-Based Recommendations

Diagnosis

  • Use 13C-urea breath test (UBT) for H. pylori status assessment.

Management

  • Consider H. pylori status when planning immunotherapy for GC patients.

Monitoring & Follow-up

  • Assess treatment efficacy every 6 weeks through clinical evaluations and imaging.

Risks

  • Exclude patients with recent infections, gastrointestinal surgery, or antibiotic use prior to immunotherapy.

Patient & Prescribing Data

Adults aged 18 years or older diagnosed with gastrointestinal cancers.

H. pylori-positive patients may respond better to immunotherapy.

Clinical Best Practices

  • Implement strict inclusion/exclusion criteria to minimize confounding variables.
  • Regularly monitor patient responses to immunotherapy using RECIST 1.1 criteria.

References

Original Source(s)

Influence of Helicobacter pylori Infection on Gut and Tumor Microbiomes and Its Relationship with Immunotherapy Outcomes in Gastrointestinal Malignancies

  • by Keren Jia, Yang Chen, Die Dai, Yi Xie, Haoxin Peng, Yanshuo Cao, Hua Zou, Chuangzhao Qiu, Yan Tan, Xiaotian Zhang, Zhihao Lu, Xiaochen Yin, Zhi Peng, Jian Li, Lin Shen

  • January 12, 2026

Related Content

A Meta-Analysis on the Effectiveness and Safety of FOLFOX Plus Bevacizumab for Colorectal Cancer Treatment

Colonoscopy-detected high-risk adenomas and their association with alcohol consumption among first-degree relatives: an observational case–control study

The right hemicolon fascial system: a narrative review